Chapter review

Must know

• ANA Code of EthicsThe ANA establishes general nursing ethics, professional conduct, and overall scope of practice boundaries, whereas the APNA and ISPN define specialty-specific psychiatric-mental health standards.

  • The ANA establishes general nursing ethics, professional conduct, and overall scope of practice boundaries, whereas the APNA and ISPN define specialty-specific psychiatric-mental health standards.
  • Patient confidentiality is a primary ethical mandate under the ANA Code of Ethics, but it is legally superseded when an explicit, credible threat is made against an identifiable third party, triggering the mandatory duty to warn and protect.
  • National certification board exams (ANCC and AANPCB) evaluate candidate decision-making based on these national standards of care rather than local clinic habits, regional routines, or preceptor prescribing preferences.
  • Advanced practice roles extend beyond conventional clinical care into health coaching, clinical education, interprofessional consultation, and quality improvement initiatives across outpatient, inpatient, and consultation-liaison settings.
• Spoken Teaching: Professional Standards, Scope, and Ethical PrinciplesAutonomy: Respecting the patient's moral and legal right to make self-determined healthcare choices when decision-making capacity is present.

  • Autonomy: Respecting the patient's moral and legal right to make self-determined healthcare choices when decision-making capacity is present.
  • Beneficence: Acting in the best interest of the patient to promote health, healing, and emotional stability.
  • Nonmaleficence: Fulfilling the mandatory obligation to do no harm, preventing unnecessary risk, and avoiding unsafe clinical practices.
  • Justice: Ensuring equitable, unbiased treatment and equal allocation of healthcare resources across diverse patient populations.
  • Fidelity: Demonstrating faithfulness to professional promises, maintaining clinical loyalty, and fulfilling contractual duties.
  • Veracity: Maintaining complete honesty and truthfulness in patient communication and clinical documentation.
• Practice SignpostsWhen facing legal, ethical, or scope-of-practice exam items, the first-line decision must always align directly with national evidence-based guidelines and established professional standards of practice.

  • Immediate physical safety and mandatory reporting laws (such as child abuse, elder abuse, or active threats of violence against a specific individual) always take priority over routine confidentiality preferences.
  • When facing legal, ethical, or scope-of-practice exam items, the first-line decision must always align directly with national evidence-based guidelines and established professional standards of practice.

  Board trap. Do not select answer choices that rely on local clinic habits, regional workarounds, or waiting for preceptor or physician directions. The exam assumes you operate as an independent prescriber guided by national standards established by the ANA, APNA, and ISPN. Another trap is fa

  Safety. Immediate physical safety and mandatory reporting laws (such as child abuse, elder abuse, or active threats of violence against a specific individual) always take priority over routine confidentiality preferences.

• Ethical Decision-Making TheoriesAutonomy grants competent adult patients the absolute right to self-determination, including accepting or refusing psychiatric treatment and informed consent, which can only be overridden during immediate physical safety emergencies or formal civil commitment.

  • Autonomy grants competent adult patients the absolute right to self-determination, including accepting or refusing psychiatric treatment and informed consent, which can only be overridden during immediate physical safety emergencies or formal civil commitment.
  • Beneficence requires the PMHNP to actively promote the patient's well-being and health, while nonmaleficence mandates doing no harm, establishing the clinical rule that physical safety and emergency stabilization always take priority over elective interventions.
  • In ethical dilemma resolution, the first-line step is always systematic assessment: gathering clinical facts, identifying conflicting ethical principles, clarifying patient decision-making capacity, and analyzing legal constraints before selecting an intervention.
  • A primary board trap is confusing paternalism with beneficence: overriding a competent patient's refusal of treatment because the clinician believes it is in their best interest violates autonomy and constitutes an unethical breach of practice standards.
• Deontological TheoryWhat it is: Rooted in Kantian ethics, deontological theory asserts that actions are inherently right or wrong based on duty, moral rules, and obligations, regardless of the ultimate outcome or consequences.

  • What it is: Rooted in Kantian ethics, deontological theory asserts that actions are inherently right or wrong based on duty, moral rules, and obligations, regardless of the ultimate outcome or consequences.
  • Duty is absolute. An action is moral only if it fulfills a mandatory obligation.
  • Typical board clue: A provider adheres strictly to confidentiality or legal disclosure rules because it is the required professional duty.
• Teleological Theory (Utilitarianism)What it is: Teleological theory, also known as consequentialism or utilitarianism, judges the morality of an action strictly by its outcomes, striving to achieve the greatest good for the greatest number of people.

  • What it is: Teleological theory, also known as consequentialism or utilitarianism, judges the morality of an action strictly by its outcomes, striving to achieve the greatest good for the greatest number of people.
  • Why boards care: Tested in public health scenarios, emergency triage, and clinic policy decisions where limited resources must be allocated to maximize community benefit.
  • Morality is calculated by net utility: maximum benefit and minimum overall harm across a population.
  • Typical board clue: A clinic policy or triage decision designed to benefit the largest group of patients.
• Virtue EthicsWhat it is: Virtue ethics centers on the character, moral integrity, and core virtues of the practitioner rather than rigid adherence to rules or outcome calculations.

  • What it is: Virtue ethics centers on the character, moral integrity, and core virtues of the practitioner rather than rigid adherence to rules or outcome calculations.
  • Why boards care: Underpins expectations of professional conduct, empathy, and personal integrity in advanced practice nursing.
  • Focuses on what a virtuous, compassionate, and wise clinician would do in a given scenario.
• Core Ethical PrinciplesAutonomy: Respecting the patient's right to self-determination, independence, and personal liberty. This principle governs voluntary psychiatric admission, choice of therapy, and informed consent.

  • Autonomy: Respecting the patient's right to self-determination, independence, and personal liberty. This principle governs voluntary psychiatric admission, choice of therapy, and informed consent.
  • Beneficence: The professional duty to act for the benefit of the patient, actively promoting health, mental stability, and access to evidence-based care.
  • Nonmaleficence: The obligation to do no harm. This principle guides psychopharmacotherapy safety, avoiding unnecessary polypharmacy, and preventing treatment-induced complications like metabolic syndrome or toxicity.
  • Justice: The duty to treat all individuals fairly and equitably, ensuring equal distribution of healthcare resources without bias related to socioeconomic status, diagnosis, race, or background.
  • Fidelity: Faithfulness, loyalty, and honoring promises made within the therapeutic nurse practitioner patient relationship.
  • Veracity: Direct truthfulness and honesty. The PMHNP must provide accurate, clear information regarding diagnostic findings, medication side effects, treatment options, and realistic prognoses.
• Key Exam SignpostsThe initial step when resolving an ethical dilemma is always systematic assessment. The PMHNP must first clarify the clinical facts, evaluate patient decision-making capacity, identify the specific conflicting ethical principles, and review relevant legal statutes before taking a

  • - **First-line**: The initial step when resolving an ethical dilemma is always systematic assessment.
  • The PMHNP must first clarify the clinical facts, evaluate patient decision-making capacity, identify the specific conflicting ethical principles, and review relevant legal statutes before taking action.
  • - **Safety alert**: Immediate physical safety overrides individual **autonomy** when a patient presents an imminent threat of violence or suicide.
  • In emergency situations involving active danger, **nonmaleficence** and **beneficence** dictate immediate physical stabilization and crisis intervention over elective autonomy.

  Board trap. Test-writers frequently set traps by presenting a competent adult patient who refuses a recommended psychotropic medication or diagnostic procedure. Choosing to force treatment or tricking the patient under the guise of beneficence is paternalism and represents an unethical, test

  Safety. Immediate physical safety overrides individual autonomy when a patient presents an imminent threat of violence or suicide. In emergency situations involving active danger, nonmaleficence and beneficence dictate immediate physical stabilization and crisis intervention over electiv

• Ethical Dilemmas and DistressCore ethical principles (autonomy, beneficence, nonmaleficence, justice, fidelity, veracity) form the non-negotiable foundation of PMHNP board exam scenarios.

  • Core ethical principles (autonomy, beneficence, nonmaleficence, justice, fidelity, veracity) form the non-negotiable foundation of PMHNP board exam scenarios.
  • An ethical dilemma occurs when two compelling ethical principles conflict, such as a competent adult patient exercising autonomy by refusing psychotropic medication versus the provider's desire for beneficence.
  • Moral distress arises when the clinician knows the ethically correct action but is blocked from executing it due to organizational, legal, or administrative constraints.
  • Involuntary psychiatric commitment requires documented imminent danger to self, danger to others, or grave disability, occurring within specific emergency timelines (typically 72-hour observation periods depending on state jurisdiction).
  • Involuntary admission does not automatically strip a patient of the right to refuse medications, except during acute, life-threatening emergency situations where immediate physical harm is present.
  • The Tarasoff duty to warn and protect mandates breaching confidentiality when a patient expresses a specific, plausible threat of violence toward an identifiable victim.
• Core Ethical Principles FrameworkAutonomy: Patient right to self-determination and independent decisions. Requires assessing decision-making capacity and obtaining voluntary informed consent.

  • Autonomy: Patient right to self-determination and independent decisions. Requires assessing decision-making capacity and obtaining voluntary informed consent.
  • Beneficence: Duty to act in the best interest of the patient and promote overall well-being.
  • Nonmaleficence: Primary obligation to do no harm, avoiding unsafe prescribing, premature discharge, or inappropriate interventions.
  • Justice: Fair and equal distribution of mental health resources and standard of care regardless of patient background or practice setting.
  • Fidelity: Honoring commitments, maintaining trust, and upholding professional boundaries.
  • Veracity: Obligation to tell the complete truth to patients regarding diagnoses, treatment risks, and clinical prognosis.
• Ethical Dilemmas vs Moral DistressEthical Dilemma: Conflict between two valid moral obligations where choosing one violates the other. Resolution requires prioritizing patient safety, legal mandates, and capacity.

  • Ethical Dilemma: Conflict between two valid moral obligations where choosing one violates the other. Resolution requires prioritizing patient safety, legal mandates, and capacity.
  • Moral Distress: Internal frustration when professional ethics dictate one clear action, but workplace policy, financial constraints, or administrative mandates prevent the clinician from acting correctly.
• Autonomy vs BeneficenceThink: Patient choice versus provider helpfulness.

  • Think: Patient choice versus provider helpfulness.
  • Priority: Patient autonomy overrides provider beneficence if the patient has intact clinical decision-making capacity and no imminent life threat.
  • Boards are testing: Recognizing that competent adults have the legal right to make decisions that providers disagree with.
  • Mini example: A stable adult with schizophrenia refuses second-generation antipsychotic maintenance therapy due to weight gain concerns.
• Involuntary Admission vs Involuntary TreatmentThink: Holding a patient for evaluation versus forcing medication administration.

  • Think: Holding a patient for evaluation versus forcing medication administration.
  • Priority: Involuntary status allows physical confinement for safety, but a separate legal process or immediate physical emergency is required to administer forced psychotropics.
  • Boards are testing: Understanding that involuntary admission does not eliminate the constitutional right to refuse non-emergency medical treatment.
  • Mini example: An involuntarily committed patient with bipolar mania refuses oral lithium. Forced administration is illegal unless an immediate threat of bodily harm exists or a court order is granted.
• Tarasoff Duty vs Patient ConfidentialityThink: Mandatory breach for public safety versus strict privacy protection.

  • Think: Mandatory breach for public safety versus strict privacy protection.
  • Priority: Immediate physical safety of an intended victim overrides HIPAA and clinician-patient privilege.
  • Boards are testing: Identifying specific, named targets of explicit violence as the trigger for duty to warn and protect.
  • Mini example: A patient states a specific plan to shoot a designated coworker upon discharge. The PMHNP must notify law enforcement and the named coworker.
• First-lineFirst-line approach: Always assess patient decision-making capacity and physical safety before taking administrative, legal, or involuntary action.

  • First-line approach: Always assess patient decision-making capacity and physical safety before taking administrative, legal, or involuntary action.
• Safety AlertImmediate physical danger to self or others overrides patient confidentiality and standard autonomous decision-making rights.

  • Immediate physical danger to self or others overrides patient confidentiality and standard autonomous decision-making rights.

  Safety. Immediate physical danger to self or others overrides patient confidentiality and standard autonomous decision-making rights.

• Board TrapSelecting involuntary medication administration simply because a patient is involuntarily committed to an inpatient psychiatric unit. Involuntary hold does not equal forced drugging.

  • Selecting involuntary medication administration simply because a patient is involuntarily committed to an inpatient psychiatric unit. Involuntary hold does not equal forced drugging.

  Board trap. Selecting involuntary medication administration simply because a patient is involuntarily committed to an inpatient psychiatric unit. Involuntary hold does not equal forced drugging.

• Decisional Capacity and CompetencyDecisional capacity is a decision-specific and time-specific clinical evaluation performed by a healthcare provider at the bedside.

  • Decisional capacity is a decision-specific and time-specific clinical evaluation performed by a healthcare provider at the bedside.
  • Legal competency is a global legal status determined exclusively by a judge in a court of law, with all adults presumed competent until legally declared otherwise.
  • Evaluating decisional capacity requires assessing 4 core criteria: ability to communicate a clear choice, understand relevant clinical facts, appreciate personal applicability and consequences, and reason logically through options.
  • A psychiatric diagnosis or involuntary admission status does not automatically mean a patient lacks decisional capacity or the legal right to refuse treatment.
  • Informed consent requires 3 essential elements: voluntariness, adequate disclosure of risks, benefits, and alternatives, and verified decisional capacity.
  • When a patient lacks decisional capacity for a specific medical or psychiatric treatment decision, the PMHNP must look to advance directives or designated surrogate decision-makers (healthcare proxy or durable power of attorney for healthcare) before seeking court intervention.
• Decisional CapacityDefinition: A clinical determination of a patient's ability to make a specific healthcare decision at a given point in time.

  • Definition: A clinical determination of a patient's ability to make a specific healthcare decision at a given point in time.
  • Evaluator: Evaluated by clinicians, including PMHNPs, at the bedside.
  • Scope: Decision-specific and situational. A patient may have capacity to consent to a routine blood draw or a simple medication, but lack capacity to make complex surgical or financial choices.
  • Fluctuating nature: Capacity can fluctuate dynamically based on the patient's acute psychiatric state, delirium, intoxication, or cognitive fatigue.
  • The 4 Essential Evaluation Components:
  • 1. Communication: The patient communicates a clear, voluntary choice consistently.
• Legal CompetencyDefinition: A legal status reflecting an individual's overall civil capacity to manage their affairs and make legally binding decisions.

  • Definition: A legal status reflecting an individual's overall civil capacity to manage their affairs and make legally binding decisions.
  • Evaluator: Determined solely by a judge in a judicial proceeding. Clinicians cannot declare a patient legally incompetent.
  • Scope: Global legal status. If a judge rules an individual incompetent, a legal guardian or conservator is appointed to manage their healthcare or financial choices.
  • Presumption: All adults are presumed legally competent under national legal standards until a court rules otherwise.
• High-Yield Signposts: Safety Alerts, Board Traps, and First-Line RulesEvaluate the patient using the 4 capacity criteria (communicate, understand, appreciate, reason) at the bedside whenever a patient's decision-making ability is questioned due to severe depression, psychosis, cognitive impairment, or medical illness.

  • **Safety alert**: Assuming a psychiatric diagnosis or involuntary commitment automatically invalidates decisional capacity or strips a patient of the right to refuse medication.
  • **Board trap**: Selecting a surrogate decision-maker, spouse, or legal guardian to sign informed consent before evaluating the patient's actual decisional capacity.
  • The PMHNP must first conduct a formal clinical evaluation of the patient's capacity for the specific choice at hand.
  • Only if the patient fails the capacity evaluation should surrogate consent mechanisms be activated.

  Board trap. Selecting a surrogate decision-maker, spouse, or legal guardian to sign informed consent before evaluating the patient's actual decisional capacity. The PMHNP must first conduct a formal clinical evaluation of the patient's capacity for the specific choice at hand. Only if the pa

  Safety. Assuming a psychiatric diagnosis or involuntary commitment automatically invalidates decisional capacity or strips a patient of the right to refuse medication. Involuntary commitment restricts physical liberty due to risk of harm, but does not automatically grant the clinician au

• Involuntary Commitment PrinciplesInvoluntary commitment requires clear legal criteria including danger to self, danger to others, or severe grave disability due to mental illness.

  • Involuntary commitment requires clear legal criteria including danger to self, danger to others, or severe grave disability due to mental illness.
  • An emergency hold provides initial involuntary confinement without a prior court hearing for 48 to 72 hours to permit safety stabilization and formal evaluation.
  • Involuntarily committed patients preserve their civil rights to due process, legal counsel, and the right to petition for a writ of habeas corpus to challenge detention.
  • Involuntary admission status does not equal legal incompetence or loss of autonomy; committed patients retain the legal right to refuse treatment and psychotropic medications.
  • Emergency psychotropic medication, such as intramuscular haloperidol or lorazepam, may be administered involuntarily only during an acute emergency involving imminent physical harm.
  • If a voluntary admission patient requests discharge in writing but presents an immediate threat of danger to self or others upon evaluation, the clinician must initiate an emergency hold.
• Confidentiality and DisclosureHIPAA privacy regulations mandate that patient health information remains strictly confidential and cannot be disclosed without a signed Release of Information, except in legally specified emergencies or mandatory reporting situations.

  • HIPAA privacy regulations mandate that patient health information remains strictly confidential and cannot be disclosed without a signed Release of Information, except in legally specified emergencies or mandatory reporting situations.
  • Tarasoff duty to warn and protect requires breaching confidentiality when a patient communicates an explicit, imminent threat of serious physical harm against an identifiable third party, requiring immediate notification of law enforcement and the intended victim.
  • Mandatory abuse reporting applies to suspected child, elder, or vulnerable adult abuse and neglect; reporting to state protective agencies is legally required and does not require patient consent.
  • Court order versus subpoena: A court order signed by a judge legally mandates disclosure of medical records, whereas a standard subpoena issued by an attorney requires asserting provider-patient privilege until patient consent or a judicial order is obtained.
  • Emergency safety disclosure: When a patient presents with imminent risk of suicide, acute psychosis, or severe self-harm, confidentiality may be breached to initiate emergency psychiatric evaluation or crisis stabilization.
  • Decision-making capacity versus competency: Capacity is a time-specific clinical evaluation performed by the clinician regarding a patient's ability to understand treatment choices, while competency is a global legal status determined solely by a court judge.
• Exceptions to Confidentiality and Mandatory DisclosureThe legal duty to maintain confidentiality is not absolute and must yield when physical safety is threatened.

  • The legal duty to maintain confidentiality is not absolute and must yield when physical safety is threatened.

  Safety. The legal duty to maintain confidentiality is not absolute and must yield when physical safety is threatened.

• Medical Records, Subpoenas, and Court OrdersTest writers often attempt to trick candidates into releasing records immediately upon receiving any legal document.

  • Test writers often attempt to trick candidates into releasing records immediately upon receiving any legal document.
  • Receiving a standard attorney subpoena does not automatically authorize the release of confidential records. The PMHNP must assert provider-patient privilege and withhold documents until the patient signs a Release of Information or a judge issues a direct court order.
  • Receiving a formal court order signed by a judge requires compliance, as a court order overrides provider-patient privilege.

  Board trap. Test writers often attempt to trick candidates into releasing records immediately upon receiving any legal document.

• Confidentiality vs. PrivilegeThink: Ethical duty vs. legal evidentiary protection.

  • Think: Ethical duty vs. legal evidentiary protection.
  • Priority: Maintaining privacy in clinical care vs. withholding testimony in court.
  • Boards are testing: Confidentiality is the clinician's obligation to protect patient data from unauthorized disclosure. Privilege is the patient's legal right to prevent confidential communications from being disclosed as evidence in court proceedings.
• Subpoena vs. Court OrderThink: Attorney request vs. judicial command.

  • Think: Attorney request vs. judicial command.
  • Priority: Assert privilege first vs. comply with the law.
  • Boards are testing: A subpoena is issued by an attorney and requires patient authorization before releasing records. A court order is signed by a judge and mandates record disclosure without needing patient consent.
• Decision-Making Capacity vs. CompetencyThink: Clinical finding vs. judicial ruling.

  • Think: Clinical finding vs. judicial ruling.
  • Priority: Assessing current understanding vs. legal determination of autonomy.
  • Boards are testing: Decision-making capacity is evaluated clinically by the PMHNP for a specific medical decision at a specific moment. Competency is a formal legal designation determined only by a judge in a court of law.
• Geriatric and Cognitive Care SettingsDosing thresholds for psychotropics: When eGFR falls below 60 mL/min/1.73 m², dose adjustments are mandatory for renally eliminated psychotropics like lithium; when eGFR drops below 30 mL/min/1.73 m², metformin is strictly contraindicated due to lactic acidosis risk.

  • Dosing thresholds for psychotropics: When eGFR falls below 60 mL/min/1.73 m², dose adjustments are mandatory for renally eliminated psychotropics like lithium; when eGFR drops below 30 mL/min/1.73 m², metformin is strictly contraindicated due to lactic acidosis risk.
  • Antipsychotic black box warning: Second-generation antipsychotics carry an FDA black box warning for increased mortality when used to treat dementia-related psychosis in older adults, primarily driven by cardiovascular events, stroke, and pneumonia.
• Pharmacokinetics and Renal Function in Geriatric CareThe aging kidney experiences a baseline structural decline, decreasing renal clearance by approximately 30 percent.

  • The aging kidney experiences a baseline structural decline, decreasing renal clearance by approximately 30 percent.
  • Serum creatinine levels between 0.64 and 1.2 mg/dL often appear completely normal in older adults due to age-related sarcopenia and decreased muscle mass.
  • A normal serum creatinine reading in an elderly patient can easily mask significant renal impairment.
  • Estimated glomerular filtration rate is the single most accurate indicator of kidney function.

  Board trap. Prescribing strong CYP2D6 inhibitors to elderly patients taking cardiovascular medications is a major exam trap. SSRIs like fluoxetine and paroxetine strongly inhibit CYP2D6. Common beta-blockers such as metoprolol, atenolol, and propranolol are CYP2D6 substrates. Adding fluoxeti

  Safety. Second-generation antipsychotics carry an FDA black box warning when prescribed to elderly patients with dementia-related psychosis. Clinical trials demonstrate a statistically significant increase in mortality, predominantly resulting from heart failure, sudden cardiac death, or

• Clinical Safety and Suicide RiskAssessment of suicidal ideation begins with determining exact thought content, intent, and active plan before delegating monitoring or arranging disposition.

  • Immediate physical safety, suicide risk assessment, and acute medical stabilization take priority over routine interventions or elective therapy.
  • In military personnel and veterans, suicide risk assessment requires systematic evaluation of suicidal ideation, intent, specific plans, and access to lethal means.
  • Assessment of suicidal ideation begins with determining exact thought content, intent, and active plan before delegating monitoring or arranging disposition.
  • Co-occurring substance use disorders, particularly alcohol dependence, significantly elevate suicide risk and impulse-driven self-harm in patients with trauma or severe mental illness.
  • Assuming new-onset mood lability, anxiety, or behavioral changes in a veteran are purely primary psychiatric without ruling out medical causes, traumatic brain injury, or thyroid dysfunction with a TSH outside the normal range of 0.4 to 4.0 mIU/L.
  • Mandatory laboratory safety monitoring includes baseline absolute neutrophil count for clozapine, liver transaminases (AST and ALT, normal 0 to 40 units/L) and platelets for valproate, and serum creatinine (0.64 to 1.2 mg/dL) and eGFR (normal over 90 mL/min) for lithium.

  Board trap. Assuming new-onset mood lability, anxiety, or behavioral changes in a veteran are purely primary psychiatric without ruling out medical causes, traumatic brain injury, or thyroid dysfunction with a TSH outside the normal range of 0.4 to 4.0 mIU/L.

  Safety. Immediate physical safety, suicide risk assessment, and acute medical stabilization take priority over routine interventions or elective therapy.

• ADHD Diagnostic PearlsAge Cutoff for Onset: Several inattentive or hyperactive-impulsive symptoms must be present prior to age 12.

  • Age Cutoff for Onset: Several inattentive or hyperactive-impulsive symptoms must be present prior to age 12.
  • Cross-Setting Impairment: Symptoms and functional impairment must be clearly present in 2 or more settings, such as at home, at school, or in social activities.
  • AACAP Practice Parameters: Standardized rating scales, such as Vanderbilt or Conners scales, completed by both parents and teachers are required to verify symptom presence and severity across environments before confirming a diagnosis.
  • Safety Monitoring Standards: Baseline height, weight, blood pressure, heart rate, and targeted personal/family cardiac history must be obtained before initiating stimulants. Height and weight must be tracked at every follow-up visit to monitor for growth suppression.
• Assessment and Clinical EvaluationMedical Rule-Outs: Uncorrected vision or hearing deficits, absence seizures, thyroid dysfunction, lead toxicity, obstructive sleep apnea, and chronic sleep deprivation.

  • Medical Rule-Outs: Uncorrected vision or hearing deficits, absence seizures, thyroid dysfunction, lead toxicity, obstructive sleep apnea, and chronic sleep deprivation.
  • Psychiatric and Developmental Rule-Outs: Specific learning disorders, anxiety disorders, major depressive disorder, trauma-related disorders, adjustment disorders, and oppositional defiant disorder.
• Safety Alerts and Board TrapsMethylphenidate and amphetamine stimulant formulations are first-line for children age 6 and older. Parent training in behavior management is first-line for children ages 4 to 5.

  • Atomoxetine carries a black box warning for an increased risk of suicidal ideation in children and adolescents. Close clinical monitoring for emergent suicidal thoughts or unusual behavior changes is required during initial titration.
  • Methylphenidate and amphetamine stimulant formulations are first-line for children age 6 and older. Parent training in behavior management is first-line for children ages 4 to 5.

  Board trap. Expect test stems describing a child who exhibits severe distractibility, restlessness, or failure to complete tasks at school, but whose parents report quiet, focused behavior at home. Selecting immediate medication initiation is a classic distractor. On national exams, diagnosi

  Safety. Prior to starting stimulant therapy, the provider must perform a focused cardiac history screening for unexplained syncope, exercise-induced chest pain, or a family history of sudden cardiac death or structural heart disease. An electrocardiogram or pediatric cardiology referral

• Latine Migrant YouthBottom Line Summary

  • Bottom Line Summary

  Board trap. Test-takers often misattribute somatic complaints or health anxiety in diverse populations to primary panic or anxiety disorders without checking endocrine function; hypothyroidism presents with low energy, weight gain, mental slowness, and depression with a TSH above 4.0 mIU per

  Safety. When prescribing second generation antipsychotics such as olanzapine or clozapine in high-risk diverse populations, metabolic monitoring requires baseline weight, BMI, waist circumference, blood pressure, fasting plasma glucose, and fasting lipid profile, with weight reassessed a

• Chapter Bottom LineeGFR (>90 mL/min/1.73 m² normal): The single most accurate laboratory measurement of kidney function. When eGFR remains above 60 mL/min/1.73 m², no dosage adjustment is required for most psychotropic medications.

  • eGFR (>90 mL/min/1.73 m² normal): The single most accurate laboratory measurement of kidney function. When eGFR remains above 60 mL/min/1.73 m², no dosage adjustment is required for most psychotropic medications.
  • Serum Creatinine (0.64 to 1.2 mg/dL): A more sensitive and specific marker of kidney disease than blood urea nitrogen (BUN). However, elderly patients with reduced muscle mass often maintain a normal serum creatinine despite a significantly reduced eGFR.
  • Blood Urea Nitrogen (BUN) (8 to 18 mg/dL): Assesses renal clearance and fluid volume status. An isolated elevation in BUN with a normal serum creatinine indicates dehydration.
  • Lithium renal clearance: Lithium is eliminated unfiltered and unmetabolized by the kidneys. Co-administration with ACE inhibitors, ARBs, or thiazide diuretics reduces renal clearance and causes lithium toxicity. Beta blockers do not alter renal lithium clearance.
  • Creatine Kinase (CK) (0 to 139 U/L): Evaluates muscle injury across skeletal, cardiac, and cerebral tissue. Massive elevations into the thousands occur in neuroleptic malignant syndrome (NMS), leading to myoglobinuria and acute renal failure.
  • Metformin renal boundary: Metformin requires dosage caution when eGFR drops, and it is strictly contraindicated when eGFR is less than 30 mL/min/1.73 m² due to the risk of lactic acidosis .
• Glomerular Filtration Rate and Serum CreatinineeGFR is the first-line and most accurate objective measurement used to guide dosing for renally excreted psychotropic medications, particularly lithium.

  • eGFR is the first-line and most accurate objective measurement used to guide dosing for renally excreted psychotropic medications, particularly lithium.
  • When eGFR drops below 60 mL/min/1.73 m², the PMHNP must recalculate psychotropic dosages and monitor serum levels closely. Lithium dosage reductions or drug substitution become necessary as renal filtration declines.

  Board trap. Assuming an elderly patient has normal renal function because their serum creatinine is within the normal range of 0.64 to 1.2 mg/dL. Because creatinine generation depends on muscle mass, sarcopenic older adults can experience a 30 percent drop in eGFR while maintaining a decepti

  Safety. When eGFR drops below 60 mL/min/1.73 m², the PMHNP must recalculate psychotropic dosages and monitor serum levels closely. Lithium dosage reductions or drug substitution become necessary as renal filtration declines.

• Blood Urea Nitrogen and Hydration MetricsEvaluating the ratio of BUN to serum creatinine helps differentiate primary renal damage from prerenal azotemia caused by fluid loss.

  • Evaluating the ratio of BUN to serum creatinine helps differentiate primary renal damage from prerenal azotemia caused by fluid loss.
  • Misinterpreting a mild BUN elevation (above 18 mg/dL) as worsening renal failure when serum creatinine remains unchanged. Dehydration alone elevates BUN, which in turn concentrates serum lithium levels and increases the risk of toxicity.

  Board trap. Misinterpreting a mild BUN elevation (above 18 mg/dL) as worsening renal failure when serum creatinine remains unchanged. Dehydration alone elevates BUN, which in turn concentrates serum lithium levels and increases the risk of toxicity.

• Renal Drug Interactions with LithiumWhen initiating antihypertensive therapy for a patient taking lithium, selecting a beta blocker or a calcium channel blocker is safer because these drug classes do not impair renal clearance of lithium.

  • Adding an ACE inhibitor, an angiotensin II receptor blocker (ARB), or a thiazide diuretic to a patient on stable lithium therapy reduces renal drug elimination and induces lithium toxicity. Patients present with lethargy, weakness, coarse tremors, blurred vision, and confusion.
  • When initiating antihypertensive therapy for a patient taking lithium, selecting a beta blocker or a calcium channel blocker is safer because these drug classes do not impair renal clearance of lithium.

  Safety. Adding an ACE inhibitor, an angiotensin II receptor blocker (ARB), or a thiazide diuretic to a patient on stable lithium therapy reduces renal drug elimination and induces lithium toxicity. Patients present with lethargy, weakness, coarse tremors, blurred vision, and confusion.

• Creatine Kinase and Muscle BreakdownWhile normal creatine kinase ranges from 0 to 139 U/L, acute elevations reaching thousands of units per liter signal severe rhabdomyolysis or neuroleptic malignant syndrome (NMS). Severe rigidity breaks down skeletal muscle, releasing myoglobin into the circulation.

  • While normal creatine kinase ranges from 0 to 139 U/L, acute elevations reaching thousands of units per liter signal severe rhabdomyolysis or neuroleptic malignant syndrome (NMS). Severe rigidity breaks down skeletal muscle, releasing myoglobin into the circulation.
  • Mistaking NMS muscle rigidity and high CK for simple motor restlessness or dystonia. Myoglobinuria turns urine dark and clogs renal tubules, making immediate IV hydration and ICU admission essential to prevent acute renal failure.

  Board trap. Mistaking NMS muscle rigidity and high CK for simple motor restlessness or dystonia. Myoglobinuria turns urine dark and clogs renal tubules, making immediate IV hydration and ICU admission essential to prevent acute renal failure.

  Safety. While normal creatine kinase ranges from 0 to 139 U/L, acute elevations reaching thousands of units per liter signal severe rhabdomyolysis or neuroleptic malignant syndrome (NMS). Severe rigidity breaks down skeletal muscle, releasing myoglobin into the circulation.

• Endocrine: Thyroid Function PanelsNormal TSH reference range: Thyroid stimulating hormone ranges from 0.4 to 4.0 mIU/L. It evaluates anterior pituitary hormone release directing thyroid gland T4 secretion.

  • Normal TSH reference range: Thyroid stimulating hormone ranges from 0.4 to 4.0 mIU/L. It evaluates anterior pituitary hormone release directing thyroid gland T4 secretion.
  • Normal Free T4 reference range: Free, metabolically active unbound thyroxine ranges from 10 to 27 pmol/L.
  • Primary hypothyroidism lab pattern: Characterized by an elevated TSH above 4.0 mIU/L (such as 24 mIU/L) and a depressed Free T4 below 10 pmol/L (such as 3 pmol/L).
  • Hyperthyroidism lab pattern: Characterized by a suppressed TSH below 0.4 mIU/L (such as 0.15 mIU/L) and an elevated Free T4 above 27 pmol/L (such as 79 pmol/L).
  • Subclinical hypothyroidism lab pattern: Characterized by a mildly elevated TSH (such as 8.9 mIU/L) alongside a normal Free T4 (such as 15 pmol/L).
  • Lithium monitoring requirement: Lithium directly inhibits thyroid hormone synthesis. Providers must check baseline TSH and recheck every 6 to 12 months.
• Keyed letter: CA. ALT and AST assess hepatic cellular damage, which is a known risk of valproate therapy.

  • A. ALT and AST assess hepatic cellular damage, which is a known risk of valproate therapy.
  • B. Bilirubin is an essential component of routine liver function monitoring during valproate therapy.
  • D. Platelet counts must be monitored because valproate can cause dose-dependent thrombocytopenia.
• Keyed letter: DA. Low TSH and elevated Free T4 indicate hyperthyroidism.

  • A. Low TSH and elevated Free T4 indicate hyperthyroidism.
  • B. Mildly elevated TSH with a normal Free T4 indicates subclinical hypothyroidism.
  • C. TSH and Free T4 within normal limits represent a normal, euthyroid state.
• Keyed letter: BA. Dismissing symptoms without objective medical evaluation violates the standard of care.

  • A. Dismissing symptoms without objective medical evaluation violates the standard of care.
  • C. Increasing antidepressant dosage is premature before ruling out an underlying endocrine etiology.
  • D. Referring to psychotherapy is an intervention that should not replace necessary medical assessment.
• GGT (Gamma-glutamyl transpeptidase)GGT Reference Range and Function: Gamma-glutamyl transpeptidase (GGT) has a normal reference range of 0 to 30 U/L and measures intrahepatic or extrahepatic cholestasis and bile flow.

  • GGT Reference Range and Function: Gamma-glutamyl transpeptidase (GGT) has a normal reference range of 0 to 30 U/L and measures intrahepatic or extrahepatic cholestasis and bile flow.
  • Alcohol Abuse Marker: GGT is a highly sensitive laboratory indicator for heavy alcohol intake and chronic alcoholic liver disease.
  • Abstinence Timeline: Patients must maintain complete alcohol abstinence for approximately 3 months before elevated GGT levels begin to decline and normalize.
  • Separate Order Requirement: GGT is not included in a standard liver function panel (which consists of AST, ALT, alkaline phosphatase, and bilirubin) and must be ordered as a separate add-on laboratory test.
• Clinical Teaching and SignpostsSafety alert: Acute neurological deficits, facial drooping, visual changes, or cranial nerve neuropathies must always be evaluated as organic physical disorders or medical emergencies before attributing symptoms to psychiatric causes.

  • Safety alert: Acute neurological deficits, facial drooping, visual changes, or cranial nerve neuropathies must always be evaluated as organic physical disorders or medical emergencies before attributing symptoms to psychiatric causes.
  • Board trap: A common exam distractor confuses Cranial Nerve V with Cranial Nerve VII.
  • Remember that Cranial Nerve V controls jaw chewing and facial sensation, whereas Cranial Nerve VII controls smiling, blinking, tearing, and salivation.

  Board trap. A common exam distractor confuses Cranial Nerve V with Cranial Nerve VII. Remember that Cranial Nerve V controls jaw chewing and facial sensation, whereas Cranial Nerve VII controls smiling, blinking, tearing, and salivation.

  Safety. Acute neurological deficits, facial drooping, visual changes, or cranial nerve neuropathies must always be evaluated as organic physical disorders or medical emergencies before attributing symptoms to psychiatric causes.

• Pharmacokinetics (PK) vs. Pharmacodynamics (PD)Approximately 50 percent of all prescription medications are metabolized through the CYP3A4 pathway, including alprazolam, sildenafil, atorvastatin, simvastatin, cyclosporine, and oral contraceptives.

  • Approximately 50 percent of all prescription medications are metabolized through the CYP3A4 pathway, including alprazolam, sildenafil, atorvastatin, simvastatin, cyclosporine, and oral contraceptives.
  • Fluoroquinolone antibiotics like ciprofloxacin and the SSRI fluvoxamine are potent CYP1A2 inhibitors that block the clearance of olanzapine and clozapine, resulting in elevated antipsychotic levels and excessive sedation.
  • Inducers accelerate enzymatic activity and lower substrate serum levels, risking therapeutic failure ("inducer makes substrate go low"). Strong CYP3A4 inducers like oxcarbazepine, carbamazepine, and St. John's wort reduce oral contraceptive levels, causing contraceptive failure.
  • Carbamazepine acts as a broad auto-inducer across CYP1A2, CYP2C19, CYP3A4, and CYP3A5, requiring dose adjustments and monitoring for co-administered psychotropic and medical drugs.
• Pharmacodynamics (PD) vs. Pharmacokinetics (PK)When prescribing for elderly or medically complex patients, first-line strategy minimizes PK drug interactions by choosing psychotropics with low CYP450 binding affinity, such as citalopram, escitalopram, or sertraline.

  • When prescribing for elderly or medically complex patients, first-line strategy minimizes PK drug interactions by choosing psychotropics with low CYP450 binding affinity, such as citalopram, escitalopram, or sertraline.
• CYP450 Isoenzyme SubstratesWhat it is: A substrate is a medication or substance that utilizes a specific CYP450 enzymatic pathway to be modified, reach its site of action, or be eliminated from the body.

  • What it is: A substrate is a medication or substance that utilizes a specific CYP450 enzymatic pathway to be modified, reach its site of action, or be eliminated from the body.
  • CYP2D6 Substrates: Include fluoxetine, paroxetine, sertraline, venlafaxine, duloxetine, tricyclic antidepressants (TCAs), haloperidol, risperidone, iloperidone, aripiprazole, antiarrhythmics, and beta blockers with the -olol suffix (metoprolol, atenolol, propranolol).
  • CYP1A2 Substrates: Include duloxetine, mirtazapine, clozapine, olanzapine, and asenapine.
  • CYP3A4 Substrates: Account for roughly 50 percent of all prescription drugs, including sildenafil, atorvastatin, simvastatin, venlafaxine, alprazolam, cyclosporine, and oral contraceptives.
• CYP450 Isoenzyme InhibitorsWhat it is: An inhibitor blocks a specific enzymatic pathway, preventing substrate clearance. This leads to elevated substrate serum levels and substrate-induced toxicity.

  • What it is: An inhibitor blocks a specific enzymatic pathway, preventing substrate clearance. This leads to elevated substrate serum levels and substrate-induced toxicity.
  • CYP2D6 Inhibitors: Include fluoxetine, paroxetine, bupropion, and duloxetine. Notice that fluoxetine, paroxetine, and duloxetine serve as both substrates and inhibitors of CYP2D6.
  • CYP1A2 Inhibitors: Include fluvoxamine, fluoxetine, paroxetine, sertraline, cimetidine, and fluoroquinolones like ciprofloxacin.
  • CYP3A4 Inhibitors: Include macrolide antibiotics such as erythromycin and clarithromycin.

  Safety. Adding a CYP2D6 inhibitor like fluoxetine to a patient taking a beta blocker inhibits clearance, causing toxic accumulation that produces symptomatic bradycardia, hypotension, dizziness, and presyncope. Adding a CYP1A2 inhibitor like ciprofloxacin to a patient taking olanzapine b

• CYP450 Isoenzyme InducersWhat it is: An inducer accelerates enzymatic activity, pushing the substrate through the metabolic pathway faster. This leads to reduced substrate serum levels and loss of therapeutic efficacy.

  • What it is: An inducer accelerates enzymatic activity, pushing the substrate through the metabolic pathway faster. This leads to reduced substrate serum levels and loss of therapeutic efficacy.
  • CYP3A4 Inducers: Include St. John's wort, oxcarbazepine, and carbamazepine.
  • CYP1A2 Inducers: Include omeprazole, carbamazepine, and tobacco smoke.

  Board trap. When an inhibitor like ciprofloxacin increases olanzapine sedation in a stable patient who is finishing a short antibiotic course, test-takers often fall for the trap of ordering an emergency department referral for delirium or stopping the antibiotic early. If the mental status

  Safety. Co-administering a CYP3A4 inducer like oxcarbazepine, carbamazepine, or St. John's wort with CYP3A4 substrates causes rapid drug breakdown. This creates a high risk for oral contraceptive failure (unintended pregnancy), antiretroviral failure in HIV management, or cyclosporine fa

• OLD CART Diagnostic MnemonicOnset (O): Identifies the exact time and speed of symptom emergence, which is essential to distinguish acute medical emergencies like delirium (sudden onset) from chronic psychiatric conditions like dementia or major depression.

  • Onset (O): Identifies the exact time and speed of symptom emergence, which is essential to distinguish acute medical emergencies like delirium (sudden onset) from chronic psychiatric conditions like dementia or major depression.
  • Location (L): Pinpoints the specific physical, anatomical, or localized cognitive domain affected by the chief complaint.
  • Duration (D): Establishes symptom longevity to satisfy exact DSM-5-TR diagnostic criteria, such as 2 weeks for major depressive disorder, 6 months for generalized anxiety disorder or somatic symptom disorder, and 3 nights per week for at least 3 months for insomnia disorder.
  • Characteristics (C): Evaluates symptom quality, severity, and presentation pattern, helping differentiate episodic panic attacks from persistent generalized anxiety or somatic distress.
  • Aggravating (A) and Relieving (R) Factors: Identifies specific environmental, physiological, or psychological triggers and alleviating mechanisms.
  • Treatment (T): Documents past and current pharmacological or psychotherapeutic interventions, exact dosages, adherence, and clinical responses to avoid repeating ineffective or toxic treatments.
• High-Yield Spoken Teaching: OLD CART Diagnostic MnemonicThe OLD CART mnemonic serves as your primary systematic framework for history taking and symptom analysis in psychiatric mental health practice.

  • The OLD CART mnemonic serves as your primary systematic framework for history taking and symptom analysis in psychiatric mental health practice.
  • Boards test your ability to collect structured subjective data before leaping to diagnosis or treatment.
  • When evaluating a chief complaint, you must systematically walk through each element of OLD CART: Onset, Location, Duration, Characteristics, Aggravating factors, Relieving factors, and Treatment.
  • In psychiatric practice, establishing **Onset** and **Duration** provides the diagnostic backbone for timeline-dependent DSM-5-TR disorders.

  Board trap. Test writers frequently present clinical vignettes where a patient reports distress, and the distractors offer immediate psychotropic prescribing or psychotherapy referral. Choosing an intervention before completing a thorough symptom history and physical rule-out is a classic bo

  Safety. When a patient presents with active suicidal ideation, severe agitation, or sudden confusion, broad history taking must pause immediately. You must pivot directly to targeted, closed-ended questions to evaluate immediate physical safety, suicide plan, intent, access to lethal mea

• Implicit Association Test (IAT)Valproate monitoring requires baseline and routine AST, ALT, bilirubin, and platelet counts. Discontinue valproate immediately if transaminases exceed 2 to 3 times the upper limit of normal, such as an AST of 240 units per liter or ALT of 132 units per liter.

  • Valproate monitoring requires baseline and routine AST, ALT, bilirubin, and platelet counts. Discontinue valproate immediately if transaminases exceed 2 to 3 times the upper limit of normal, such as an AST of 240 units per liter or ALT of 132 units per liter.
  • Second-generation antipsychotic metabolic monitoring requires baseline BMI, waist circumference, blood pressure, fasting glucose, and fasting lipids. Recheck weight at 4, 8, and 12 weeks, and recheck blood pressure, fasting glucose, and lipids at 12 weeks and annually.
  • CYP450 enzyme interactions dictate prescribing safety. Ciprofloxacin inhibits CYP1A2, blocking olanzapine metabolism and causing excess sedation. Oxcarbazepine and carbamazepine induce CYP3A4, accelerating oral contraceptive clearance and causing contraceptive failure.
  • Thyroid dysfunction mimics psychiatric illness. Primary hypothyroidism presents with an elevated TSH above 4.0 mIU/L and a low free T4 below 10 pmol/L. Always order a TSH before initiating or increasing psychotropics for new-onset postpartum anxiety or depression.
  • Cranial nerve assessments test specific localized functions. Cranial nerve V (trigeminal) controls facial sensation and mastication. Cranial nerve VII (facial) controls facial expressions, tearing, and salivation; acute paralysis of cranial nerve VII causes Bell's palsy.
• CYP450 Substrates vs. Inhibitors vs. InducersThink Substrates: Medications that rely on a specific CYP450 isoenzyme pathway for metabolism and elimination. Examples include fluoxetine (CYP2D6), olanzapine (CYP1A2), and alprazolam (CYP3A4).

  • Think Substrates: Medications that rely on a specific CYP450 isoenzyme pathway for metabolism and elimination. Examples include fluoxetine (CYP2D6), olanzapine (CYP1A2), and alprazolam (CYP3A4).
  • Think Inhibitors: Medications that block the enzymatic pathway, preventing substrate breakdown, elevating substrate serum levels, and causing toxicity. Examples include ciprofloxacin (CYP1A2) and fluvoxamine (CYP1A2).
  • Think Inducers: Medications that stimulate enzymatic activity, accelerating substrate clearance, lowering substrate serum levels, and causing treatment failure. Examples include carbamazepine, oxcarbazepine, and St. John's wort (CYP3A4).
  • Priority Difference: Inhibitors cause toxicity from elevated substrate levels. Inducers cause treatment failure from reduced substrate levels.
• Somatic Symptom Disorder vs. Illness Anxiety Disorder vs. Conversion DisorderThink Somatic Symptom Disorder: Distressing, real physical symptoms accompanied by excessive anxiety, thoughts, and time devoted to symptoms lasting at least 6 months.

  • Think Somatic Symptom Disorder: Distressing, real physical symptoms accompanied by excessive anxiety, thoughts, and time devoted to symptoms lasting at least 6 months.
  • Think Illness Anxiety Disorder: Preoccupation with having or acquiring a serious illness where physical symptoms are absent or minimal, lasting at least 6 months.
  • Think Functional Neurological Symptom Disorder (Conversion Disorder): Altered voluntary motor or sensory function, such as non-epileptic seizures or sudden paralysis, incompatible with recognized neurological conditions.
  • Priority Difference: Somatic symptom disorder involves prominent physical complaints. Illness anxiety disorder involves health fear without major physical symptoms. Conversion disorder involves acute neurological deficits without organic pathology.
• Hepatitis B vs. Hepatitis C TransmissionThink Hepatitis B: Efficiently transmitted through blood, body fluids, and sexual contact. Immunization is available using a 3-dose vaccine series.

  • Think Hepatitis B: Efficiently transmitted through blood, body fluids, and sexual contact. Immunization is available using a 3-dose vaccine series.
  • Think Hepatitis C: Efficiently transmitted through direct blood-to-blood contact, such as shared needles or unsterile tattooing. Sexual transmission is inefficient and vertical transmission is low.
  • Priority Difference: Hepatitis B requires post-exposure prophylaxis with hepatitis B immune globulin and vaccination for non-immune contacts. Hepatitis C requires direct-acting antiviral therapy.
• CYP 2D6 and 3A4 Focal PointsCYP 2D6 substrates include fluoxetine, paroxetine, sertraline, venlafaxine, duloxetine, all TCAs, haloperidol, risperidone, iloperidone, aripiprazole, beta-blockers ending in -olol (metoprolol, atenolol, propranolol), and antiarrhythmics.

  • CYP 2D6 substrates include fluoxetine, paroxetine, sertraline, venlafaxine, duloxetine, all TCAs, haloperidol, risperidone, iloperidone, aripiprazole, beta-blockers ending in -olol (metoprolol, atenolol, propranolol), and antiarrhythmics.
  • CYP 2D6 inhibitors include fluoxetine, paroxetine, bupropion, and duloxetine. Fluoxetine, paroxetine, and duloxetine act as both substrates and potent inhibitors of the 2D6 pathway.
  • CYP 3A4 scope accounts for approximately 50 percent of all prescription medications. Substrates include sildenafil, atorvastatin, simvastatin, venlafaxine, and alprazolam.
  • CYP 3A4 inhibitors include macrolide antibiotics such as erythromycin and clarithromycin, which block metabolic clearance and elevate 3A4 substrate concentrations toward toxicity.
  • CYP 3A4 inducers include carbamazepine, oxcarbazepine, and St. John's Wort. These agents accelerate 3A4 metabolism, driving down target substrate levels and causing treatment failure.
  • Critical 3A4 inducer failures occur when carbamazepine or oxcarbazepine are co-administered with oral contraceptives (leading to unintended pregnancy), select antiretrovirals (leading to HIV treatment failure), or cyclosporine (leading to organ transplant rejection).
• Clinical Implications and SignpostsRecognize that adding a 2D6 inhibitor to a patient established on a 2D6 substrate will cause the substrate drug concentration to rise significantly.

  • Recognize that adding a 2D6 inhibitor to a patient established on a 2D6 substrate will cause the substrate drug concentration to rise significantly.
  • Combining a 2D6 inhibitor like fluoxetine or paroxetine with a 2D6 substrate beta-blocker like metoprolol or propranolol blocks beta-blocker clearance. This elevates beta-blocker levels, precipitating severe bradycardia, hypotension, dizziness, and presyncope.
  • Selecting fluoxetine or paroxetine in elderly patients on multiple cardiac medications. Geriatric guidelines advise avoiding fluoxetine and paroxetine due to their potent 2D6 inhibition and heightened risk of polypharmacy toxicity.

  Board trap. Selecting fluoxetine or paroxetine in elderly patients on multiple cardiac medications. Geriatric guidelines advise avoiding fluoxetine and paroxetine due to their potent 2D6 inhibition and heightened risk of polypharmacy toxicity.

  Safety. Combining a 2D6 inhibitor like fluoxetine or paroxetine with a 2D6 substrate beta-blocker like metoprolol or propranolol blocks beta-blocker clearance. This elevates beta-blocker levels, precipitating severe bradycardia, hypotension, dizziness, and presyncope.

• Tobacco Smoke as InducerTobacco smoke is a potent CYP1A2 inducer driven by polycyclic aromatic hydrocarbons produced during combustion, not by nicotine.

  • Tobacco smoke is a potent CYP1A2 inducer driven by polycyclic aromatic hydrocarbons produced during combustion, not by nicotine.
  • Major psychiatric CYP1A2 substrates include clozapine, olanzapine, duloxetine, mirtazapine, asenapine, and theophylline.
  • Smoking cessation removes CYP1A2 induction, causing drug clearance to drop rapidly and serum substrate levels to double within 2 to 4 days, leading to potential severe toxicity.
  • Smoking initiation or resumption accelerates CYP1A2 enzymatic activity, dropping substrate levels and causing therapeutic failure or psychotic relapse.
  • Nicotine replacement therapy products contain nicotine without polycyclic aromatic hydrocarbons. Thus, switching from smoking to patches or gum removes the inducer, causing substrate levels to rise just like stopping cold turkey.
  • CYP1A2 inhibitors like ciprofloxacin and fluvoxamine block metabolism, elevating olanzapine or clozapine levels and causing increased sedation and adverse effects.
• Core Isoenzyme ConceptsSubstrate mechanics: A substrate is a medication that utilizes a specific enzymatic pathway for metabolism. CYP1A2 substrates include clozapine, olanzapine, duloxetine, mirtazapine, asenapine, and theophylline.

  • Substrate mechanics: A substrate is a medication that utilizes a specific enzymatic pathway for metabolism. CYP1A2 substrates include clozapine, olanzapine, duloxetine, mirtazapine, asenapine, and theophylline.
  • Inducer mechanics: An inducer accelerates isoenzyme activity. It pushes the substrate medication through the exit pathway faster, leading to a reduction in serum drug levels and potential treatment failure.
  • Inhibitor mechanics: An inhibitor blocks the isoenzyme pathway. It limits substrate clearance, making serum drug levels go high and creating a risk for drug-induced toxicity.
• Clinical Dynamics of Tobacco SmokeCombustion hydrocarbons: Polycyclic aromatic hydrocarbons in tobacco smoke induce the CYP1A2 enzyme. Nicotine itself does not affect this pathway.

  • Combustion hydrocarbons: Polycyclic aromatic hydrocarbons in tobacco smoke induce the CYP1A2 enzyme. Nicotine itself does not affect this pathway.
  • Effects of quitting smoking: When a patient on clozapine or olanzapine stops smoking, CYP1A2 activity normalizes over several days. Without enzyme induction, drug metabolism slows, causing serum levels to rise significantly.
  • Effects of resuming smoking: Resuming tobacco smoking induces CYP1A2, accelerating clearance and lowering drug concentrations, which can precipitate a psychiatric relapse.
  • Role of nicotine replacement therapy: Transdermal nicotine, gum, and lozenges lack polycyclic aromatic hydrocarbons. Substituting cigarettes with nicotine replacement therapy removes the inducer, leading to increased serum psychotropic levels.
• Key SignpostsThe first-line strategy during planned smoking cessation for patients on clozapine or olanzapine is to reduce the psychotropic dose by 30% to 50% and monitor plasma concentrations and adverse effects.

  • Abrupt smoking cessation in a patient taking clozapine or olanzapine can cause drug levels to double within 2 to 4 days, triggering extreme sedation, confusion, orthostatic hypotension, seizures, or severe anticholinergic toxicity.
  • The first-line strategy during planned smoking cessation for patients on clozapine or olanzapine is to reduce the psychotropic dose by 30% to 50% and monitor plasma concentrations and adverse effects.

  Board trap. Do not assume that nicotine replacement therapy maintains CYP1A2 induction. Question stems often describe a patient starting a nicotine patch who subsequently develops toxicity from olanzapine or clozapine. The trap choice incorrectly claims the nicotine patch maintains stable dr

  Safety. Abrupt smoking cessation in a patient taking clozapine or olanzapine can cause drug levels to double within 2 to 4 days, triggering extreme sedation, confusion, orthostatic hypotension, seizures, or severe anticholinergic toxicity.

• Sample Question 1A. Inducing the CYP2C19 pathway

  • A. Inducing the CYP2C19 pathway
  • B. Inhibiting the CYP3A4 pathway
  • C. Inhibiting the CYP1A2 pathway
  • D. Inducing the CYP1A2 pathway
• Sample Question 2A. Refer her to the emergency department for a delirium workup

  • A. Refer her to the emergency department for a delirium workup
  • B. Have her stop her ciprofloxacin and call her primary care provider in the morning
  • C. Reassure her of increased symptoms and schedule a follow-up in three days
  • D. Schedule her for a sleep study
• Creatine Kinase (CK) and Muscle LabsCreatine kinase (CK / CPK) normal reference range is 0 to 139 U/L, measuring cellular injury across skeletal muscle, cardiac tissue, and brain tissue.

  • Creatine kinase (CK / CPK) normal reference range is 0 to 139 U/L, measuring cellular injury across skeletal muscle, cardiac tissue, and brain tissue.
  • In psychiatric practice, creatine kinase is the cardinal laboratory marker for Neuroleptic Malignant Syndrome (NMS), caused most frequently by first-generation antipsychotics and less commonly by second-generation antipsychotics.
  • Severe, generalized muscle rigidity in Neuroleptic Malignant Syndrome causes acute rhabdomyolysis, driving creatine kinase levels from the normal baseline into the thousands of U/L.
  • Severe muscle breakdown releases myoglobin into systemic circulation, causing myoglobinuria, which poses an immediate risk of acute tubular necrosis and acute renal failure.
  • Emergency management of creatine kinase elevation from Neuroleptic Malignant Syndrome requires immediate discontinuation of the offending antipsychotic, aggressive intravenous hydration, and monitoring for hemodialysis.
  • Non-psychiatric causes of elevated creatine kinase include vigorous physical exertion, myositis, and myocardial infarction.
• Neuroleptic Malignant Syndrome and RhabdomyolysisThe essential first-line intervention upon suspecting Neuroleptic Malignant Syndrome is to immediately stop all antipsychotic medications, evaluate airway and autonomic stability, and initiate emergency medical transfer.

  • The essential first-line intervention upon suspecting Neuroleptic Malignant Syndrome is to immediately stop all antipsychotic medications, evaluate airway and autonomic stability, and initiate emergency medical transfer.

  Safety. Extreme muscle rigidity ("lead-pipe" rigidity) in Neuroleptic Malignant Syndrome causes rapid rhabdomyolysis. This elevates serum creatine kinase levels far beyond the normal 0 to 139 U/L range, often reaching several thousand U/L. The resulting clearance of myoglobin through the

• Laboratory Differentials and Clinical ComparisonsCreatine kinase (0 to 139 U/L) indicates skeletal or cardiac muscle breakdown from Neuroleptic Malignant Syndrome, myositis, or heavy physical exertion.

  • Creatine kinase (0 to 139 U/L) indicates skeletal or cardiac muscle breakdown from Neuroleptic Malignant Syndrome, myositis, or heavy physical exertion.
  • Hepatic transaminases AST and ALT (0 to 40 U/L) measure hepatocellular injury, such as from valproate toxicity or viral hepatitis.
  • GGT (0 to 30 U/L) assesses biliary stasis and serves as a sensitive indicator of chronic alcohol abuse.
  • eGFR (greater than 90 mL/min/1.73 m²) represents the most accurate measurement of kidney filtration function.

  Board trap. Do not confuse creatine kinase with serum creatinine. Creatine kinase measures muscle tissue destruction. Serum creatinine (0.64 to 1.2 mg/dL) evaluates renal filtration. In elderly patients with reduced muscle mass, serum creatinine can appear falsely normal despite significant